KBC Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

KBC Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$58K	Hold	6,947	–	–	﹤0.01%	1672
2026 Q2	$69K	Hold	6,947	–	–	﹤0.01%	1594
2026 Q1	$66K	Hold	6,947	–	–	﹤0.01%	1538
2025 Q4	$54K	Hold	6,947	–	–	﹤0.01%	1611
2025 Q3	$53K	Hold	6,947	–	–	﹤0.01%	1627
2025 Q2	$62K	Sell	6,947 -3,251	-32%	-$30.3K	﹤0.01%	1482
2025 Q1	$76K	Hold	10,198	–	–	﹤0.01%	1624
2024 Q4	$77K	Buy	10,198 +4,537	+80%	+$34.4K	﹤0.01%	1691
2024 Q3	$43K	Sell	5,661 -2,974	-34%	-$22.6K	﹤0.01%	1765
2024 Q2	$53K	Buy	+8,635	New	+$47.7K	﹤0.01%	1579

Other funds holding BCRX

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

OP Asset Management Helsinki $11.8B AUM 34.59% 1-Year Est. Return

IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

KBC Group's BCRX Position: Q3 2026 in Review

KBC Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q3 2026 at 6,947 shares worth $58K. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

KBC Group first reported a position in BCRX in Q2 2024 and has held it in 10 quarters since. The position peaked at $77K in Q4 2024. 116 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

KBC Group held 6,947 shares of BioCryst Pharmaceuticals worth $58K as of Q3 2026.
KBC Group left its BioCryst Pharmaceuticals share count unchanged in Q3 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1672 holding.
KBC Group first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
KBC Group's BioCryst Pharmaceuticals position peaked at $77K in Q4 2024.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.